search button

In vitro study on reversal of ovarian cancer cell resistance to cisplatin by naringin via the nuclear factor-κB signaling pathway

  • Authors:
    • Hong Zhu
    • Jun Gao
    • Lei Wang
    • Ke‑Jian Qian
    • Li‑Ping Cai

  • View Affiliations

  • Published online on: January 4, 2018     https://doi.org/10.3892/etm.2018.5695
  • Pages: 2643-2648
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the mechanism of action by which naringin reverses the resistance of ovarian cancer cells to cisplatin. Semi‑quantitative reverse transcription polymerase chain reaction (RT‑PCR) and western blotting assays were used to detect the effects of different concentrations of naringin on the expressions of nuclear factor (NF)‑κB and P‑glycoprotein (P‑gp) in the SKOV3/CDDP cell line. Small interfering RNA (siRNA) targeting NF‑κB was designed and synthesized to silence NF‑κB, and recombinant plasmid vectors overexpressing NF‑κB were constructed to transfect cells. RT‑qPCR and western blotting assays were subsequently performed to detect the effects of NF‑κB on the expression of P‑gp at the mRNA and protein levels. Naringin was added to the NF‑κB‑overexpressing SKOV3/CDDP cells and cultured for 48 h, followed by the detection of the expression of P‑gp. RT‑PCR and western blotting results demonstrated that the gene and protein expressions of NF‑κB and P‑gp were significantly decreased in a dose‑dependent manner by naringin treatment (P<0.05). In cells overexpressing NF‑κB, P‑gp expression was significantly elevated (P<0.05), and the expression of P‑gp was significantly decreased when NF‑κB was silenced (P<0.05). Treatment with naringin was able to significantly ameliorate the NF‑κB‑induced overexpression of P‑gp (P<0.05). These results indicate that naringin is able to inhibit the expression of NF‑κB and P‑gp in SKOV3/CDDP cells. Such an inhibitory effect may increase gradually with concentration, and is associated with blockade of the NF‑κB signaling pathway. This pathway may represent one of the mechanisms of action by which Naringin reverses resistance to platinum‑based agents in ovarian cancer cells.
View Figures
View References

Related Articles

Journal Cover

March-2018
Volume 15 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu H, Gao J, Wang L, Qian KJ and Cai LP: In vitro study on reversal of ovarian cancer cell resistance to cisplatin by naringin via the nuclear factor-κB signaling pathway. Exp Ther Med 15: 2643-2648, 2018
APA
Zhu, H., Gao, J., Wang, L., Qian, K., & Cai, L. (2018). In vitro study on reversal of ovarian cancer cell resistance to cisplatin by naringin via the nuclear factor-κB signaling pathway. Experimental and Therapeutic Medicine, 15, 2643-2648. https://doi.org/10.3892/etm.2018.5695
MLA
Zhu, H., Gao, J., Wang, L., Qian, K., Cai, L."In vitro study on reversal of ovarian cancer cell resistance to cisplatin by naringin via the nuclear factor-κB signaling pathway". Experimental and Therapeutic Medicine 15.3 (2018): 2643-2648.
Chicago
Zhu, H., Gao, J., Wang, L., Qian, K., Cai, L."In vitro study on reversal of ovarian cancer cell resistance to cisplatin by naringin via the nuclear factor-κB signaling pathway". Experimental and Therapeutic Medicine 15, no. 3 (2018): 2643-2648. https://doi.org/10.3892/etm.2018.5695